Keros Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-28.7M | $-23.7M | $-23.5M | $-7.3M | $-30.7M | $148.5M | $-46.0M | $-53.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $402.0K | $403.0K | $400.0K | $395.0K | $370.0K | $344.0K | $332.0K | $314.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $5.4M | $6.2M | $7.3M | $4.0M | $8.5M | $8.9M | $9.2M | $8.8M |
| Net Cash from Operating Activities | $-20.4M | $-3.5M | $-27.3M | $3.2M | $-29.6M | $161.2M | $-46.0M | $-30.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $155.0K | $73.0K | $134.0K | $132.0K | $720.0K | $565.0K | $289.0K | $386.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-155.0K | $-73.0K | $-134.0K | $-132.0K | $-720.0K | $-565.0K | $-289.0K | $-386.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-3.3M | $-2.3M | $-378.6M | $140.0K | $17.0K | $4.0K | $75.5M | $155.9M |
| Net Change in Cash | $-23.9M | $-5.9M | $-406.1M | $3.3M | $-30.3M | $160.6M | $29.2M | $125.1M |
| Free Cash Flow | $-20.6M | $-3.6M | $-27.4M | $3.1M | $-30.3M | $160.6M | $-46.3M | $-30.9M |